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nated: rivaroxaban and dabigatran 150mg. The efficiency frontier was constructed 
by connecting the remaining strategies: warfarin and apixaban. Apixaban resulted 
in an incremental additional cost of 2,870€ and an incremental QALY of 0.189, cor-
responding to an ICER of 15,157€ /QALY versus warfarin. The PSA indicated that the 
probabilities for apixaban being cost-effective versus warfarin were respectively 80% 
and 90% at the informal willing-to-pay thresholds of 30,000€ and 50,000€ . Sensitivity 
analysis identified stroke risk with apixaban and intracranial hemorrhage risk with 
warfarin as the variables most influencing the results. ConClusions: Apixaban 
may be the most economically efficient alternative to warfarin in NVAF patients 
eligible for stroke prevention in France. All other strategies are dominated. However, 
uncertainty surrounding these results should be investigated through real life data.
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objeCtives: Heart failure is quite common in elderly patients with type 2-diabetes. 
Screening could potentially improve health outcomes at acceptable costs through 
early detection and adherence to current prescription guidelines. Based on a pro-
spective study the cost-effectiveness of different screening strategies to detect heart 
failure in patients aged 60 years with type 2-diabetes was assessed. Methods: 
Data obtained from our prospective study and literature were used in a Markov 
model with a lifetime horizon to evaluate the incremental cost-effectiveness ratio 
of five increasingly extensive screening strategies. Differences in survival rates 
estimated by the Seattle Heart Failure Model between patients with undetected 
versus detected heart failure, induced by medication use, were used to adjust input 
parameters for health states related to undetected heart failure. Estimates for costs, 
utilities, and transition probabilities were additionally adjusted to age and NYHA 
class. Scenario analyses were performed to evaluate the impact of screening age 
and medication prescription and effectiveness. Probabilistic sensitivity analysis 
was performed to assess robustness of the results. Results: For both men and 
women usual care (no screening) had the highest probability of being cost-effective 
when the willingness to pay (WTP) was small. For WTP values in the range of € 4,600/
QALY-€ 27,000/QALY for men and € 5,200/QALY-€ 40,000/QALY for women evaluation 
of the electronic medical record and symptoms had the highest probability of 
being cost-effective. For higher WTP values echocardiography was the preferred 
strategy. For all screening strategies cost-effectiveness improved if prescription of 
heart failure medication was optimal or screening was started at the age of 70 
years. ConClusions: Screening for heart failure through evaluation of electronic 
medical record and symptoms has favorable cost-effectiveness and echocardiog-
raphy may also be acceptable at higher WTP values. The benefits from screening 
could be much larger than currently identified when test outcomes would more 
often lead to proper medication prescription.
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objeCtives: To assess the cost-effectiveness of apixaban versus rivaroxaban in 
the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF) in 
Spain. Methods: A Markov model was developed to simulate the evolution of 
NVAF patients throughout their lifetime. Cycle’s length was 6 weeks and 10 health 
states such as stroke, bleeding and other cardiovascular complications were defined. 
Drug’s safety and efficacy outcomes were obtained from a meta-analysis of pairwise 
indirect comparisons. The analysis was made from the Spanish National Health 
System (NHS) and the societal perspective. Apixaban and rivaroxaban pharmaco-
logical costs were calculated according to their recommended doses (5 mg twice 
daily (BID) and 20 mg once-a-day (QD), respectively). The cost of NVAF complications 
and disease management were obtained from Spanish sources. An annual discount 
rate of 3.5% for costs and health outcomes was applied. Results: Model results 
illustrate that 1,000 patients with NVAF treated with apixaban during their lifetime 
could avoid numerous complications versus rivaroxaban (9 strokes, 10 intracranial 
bleedings, 1 systemic embolism, 32 major bleedings, 52 clinically relevant non major 
bleedings and 12 related deaths). The use of apixaban was associated with 0.062 life 
years (LYG) and 0.049 quality-adjusted life-years (QALYs) gained when compared to 
rivaroxaban. Due to the lower expected mortality of patients, apixaban generated 
more costs per patient vs. rivaroxaban from the NHS perspective (115 € ), but savings 
would arise from the societal perspective (-241 € ). Incremental cost-effectiveness 
ratio results were 1,855 € per LYG and 2,347 € per QALY gained for the NHS analysis. 
Apixaban was dominant (more effective and less costly than rivaroxaban) from the 
societal perspective. Deterministic and probabilistic sensitivity analyses confirmed 
these results. ConClusions: According to this analysis, apixaban is a cost-effective 
treatment compared with rivaroxaban for the prevention of stroke in patients with 
NVAF in Spain.
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objeCtives: To calculate treatment costs for patients hospitalised for heart fail-
ure (HF) and analyse associated medical resource utilisation in a real-life care set-
ting. Methods: The study was designed as a retrospective medical record review of 
a cohort of 478 patients diagnosed and hospitalised for HF (as the primary diagnosis 
for hospitalisation with ICD-10 codes I11, I13 and I50 meeting the inclusion and 
exclusion criteria of RELAX-AHF, a randomised, placebo-controlled phase III-trial 
in acute HF) in three German hospitals. Costs and medical resource utilisation for 
HF treatment were extracted from datasets according to §21 KHEntgG (Hospital 
Reimbursement Act) and patient medical records from the full year of 2011. Costs 
of HF treatment were determined according to the cost calculation scheme of the 
German Institute for the Hospital Remuneration System (InEK). A multivariate 
regression model was developed to detect incremental effects. Results: The mean 
cost per hospital stay was 3,518 € [3,203 € ; 3,833 € ; 95%CI 315 € ]. Differences in costs 
between male and female patients were not significant. The mean length of stay 
(LOS) was 8.55 days [8.0; 9.1; 95%CI 0.55] with in-hospital mortality being 5.4% (26 
of 478 patients). A total of 637 different active pharmaceutical agents and agent 
combinations were used. The percentage of patients treated with loop diuretics 
was 84%. About 8% of patients received nitrates (all formulations). The regression 
model showed a positive correlation for treatment costs with LOS and the amount 
of daily drug doses. ConClusions: This analysis highlights that HF is a condition 
that imposes considerable costs to the German health care system. Data suggests 
that there is a high use of diuretics and a low use of nitrates in a real-life care setting.
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objeCtives: To assess the cost-effectiveness of apixaban vs. dabigatran in 
stroke prevention in patients with non-valvular atrial (NVAF) fibrillation in 
Spain. Methods: A Markov model was developed, with cycles of 6 weeks, through-
out the patient’s life and 10 health states. The analysis was made from the Spanish 
National Health System (NHS) and the societal perspective. The safety and efficacy 
of the drugs was obtained from a meta-analysis of pairwise indirect comparisons. 
Drug costs, (apixaban: 5 mg twice daily (BID); dabigatran: 110 mg BID or 150 mg 
BID), NVAF complications and disease management costs were obtained from 
Spanish sources. An annual discount rate of 3.5% for costs and health outcomes 
was applied. Results: In a cohort of 1,000 patients with NVAF, apixaban could 
avoid numerous complications versus dabigatran during their lifetime (24 ischemic 
strokes and 28 related deaths vs. dabigatran 110 mg; 11 ischemic strokes, 29 bleed-
ings and 19 deaths vs. dabigatran 150 mg). The use of apixaban was associated with 
0.126 life years (LYG) and 0.107 quality-adjusted life-years (QALYs) gained when 
compared to dabigatran 110 and 150 mg, respectively. Apixaban was estimated to 
generate more costs per patient vs. dabigatran 110 mg from the NHS perspective 
(139 € ) but overall savings could arise from the societal perspective (-524 € ), with a 
cost per QALY gained of 1,299 € for the NHS. Apixaban was dominant (more effective 
and less costly than dabigatran 110 mg) from the societal perspective. The cost per 
QALY gained, from the NHS and societal perspective, compared with dabigatran 
150 mg BID was 6,591 € and 10,676 € , respectively. Deterministic and probabilistic 
sensitivity analyses confirmed the stability of these results. ConClusions: Results 
suggest that apixaban is cost-effective versus dabigatran for the prevention of stroke 
in patients with NVAF in Spain.
PCV67
aPPliCation of new frenCH guiDelineS for eConoMiC eValuationS: 
a CoSt-effeCtiVeneSS analySiS of aPixaban in PatientS witH non-
ValVular atrial fibrillation in franCe
Durand-Zaleski I.1, Cotté F.E.2, Lanitis T.3, Godard C.2, Kachaner I.4, Kongnakorn T.5,  
Gaudin A.F.6
1Santé Publique URCEco APHP, Créteil, France, 2Bristol-Myers Squibb, Rueil-Malmaison, France, 
3Evidera, London, UK, 4Pfizer, Paris, France, 5Evidera, Lexington, MA, USA, 6Bristol-Myers-Squibb, 
Rueil Malmaison, France
objeCtives: To evaluate the cost-effectiveness of apixaban in the prevention of 
stroke in patients with non-valvular atrial fibrillation (NVAF) from a French payer 
perspective. Methods: A Markov model was developed in accordance to the new 
French guidelines of the Commission for Economic Evaluation and Public Health 
(CEESP) that also recommends applying efficiency frontier. A hypothetical cohort of 
patients with NVAF, 70 years old eligible for stroke preventive treatment (CHADS2≥ 1) 
was simulated over lifetime. Clinical events modeled included strokes, systemic 
embolism, intracranial hemorrhage, other major bleeds, clinically relevant non-
major bleeds and myocardial infarction. Treatment efficacy and bleeding data was 
obtained from ARISTOTLE. Efficacy data are from published indirect comparisons. 
Acute medical costs of stroke and hemorrhage were obtained from a dedicated 
analysis of the French national hospitalization database (PMSI). Long-term medical 
costs and utility data were derived from the literature. Univariate and probabilistic 
sensitivity analyses (PSA) were also performed to assess the robustness of the model 
projections. Results: Three strategies were strictly dominated: aspirin, dabigatran 
110mg, and dabigatran in sequential dosages. Two others were extendidly domi-
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of ivabradine plus standard therapy being cost-effective at a threshold of € 36,000/
QALY was found to be 96% in both within trial and lifetime analysis. This result is 
driven by a reduction in mortality and hospitalisations and the associated costs of 
care. ConClusions: Ivabradine added to standard care could be a cost-effective 
treatment for the treatment in CHF patients in Greece.
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With 7 million deaths per year, ischaemic heart disease is the leading cause 
of mortality worldwide. In Acute Coronary Syndrome (ACS), the vast majority 
of fatal cardiovascular events occur after hospital discharge. Guidelines recom-
mend antithrombotic treatment for secondary prevention after ACS. objeCtives: 
To assess the cost-effectiveness of rivaroxaban 2.5mg BID in combination with 
standard antiplatelet therapy (ASA alone or in combination with a thienopyri-
dine [clopidogrel or ticlopidine]) versus standard antiplatelet therapy alone for 
prevention of secondary events in ACS patients from a Swedish societal perspec-
tive. Methods: A Markov model is used to capture single and multiple events, 
costs and utilities based on the time since index event to reflect clinical practice. 
For the first 2 years the model uses data from the ATLAS ACS 2-TIMI 51 clinical 
trial including efficacy, safety, treatment discontinuation and average patient 
age. After 2 years, transition probabilities were extrapolated using an exponen-
tial function method. Estimates for life expectancy, drug acquisition costs and 
other medical and indirect costs were derived from published Swedish sources. 
Cost and effects are discounted at 3.0%. Univariate and probabilistic sensitivity 
analyses were conducted with an assumed willingness to pay (WTP) threshold of 
SEK 500,000. Results: For the base case scenario, incremental life time costs are 
estimated at SEK 10,000.44 (€ 1,156), incremental QALYs at 0.14, and incremental 
cost per QALY at SEK 71,245.76 (€ 8,236). Univariate sensitivity analyses indicate 
that the results are sensitive to changes in the cost of rivaroxaban and baseline 
utility value. At an assumed WTP of SEK 500,000, rivaroxaban in combination with 
standard antiplatelet therapy is expected to be cost-effective. ConClusions: 
From a Swedish societal perspective, secondary prevention with rivaroxaban 
2.5mg BID in combination with standard antiplatelet therapy can be considered 
a cost-effective option for patients with ACS. Sensitivity analyses demonstrated 
that the results are robust.
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objeCtives: The most common cardiac arrhythmia (atrial fibrillation, AF) 
increases the risk of morbidity and mortality. We estimated the health and eco-
nomic consequences of the use of apixaban compared with warfarin reducing the 
risk of stroke in patients with AF, from the perspective of the Instituto Mexicano 
del Seguro Social (IMSS). Methods: We performed a cost-effectiveness analysis 
using a Markov model (17 health states, six-week cycles), which simulates patients 
treated with warfarin (fixed dose: 5mg/day) or apixaban (10mg/day). Patients enter 
the model at age 70 and remain there until death (disease-related or according to 
Mexican life tables). Safety, efficacy and utilities were extracted from published 
sources. The costs of warfarin and AF-related clinical events were extracted from 
IMSS sources. The cost of apixaban was provided by the manufacturer. Costs are 
expressed in US$, 2013 and a 5% per-year discount rate was applied. Years of 
life and quality adjusted life years (QALYs) gained were the health outcomes. 
Univariate and probabilistic sensitivity analyzes were performed. Results: The 
model estimated 7.645 life years and 5.454 QALYs in the apixaban arm, which 
means 0.147 and 0.160 gained life years and QALY’s, respectively (regarding war-
farin). The costs of apixaban and warfarin were US$14,943 and US$15,042, respec-
tively (apixaban is a dominant alternative). Health gains with apixaban are driven 
by fewer event-related deaths (10/1000 patients at risk) as well as fewer hemor-
rhagic strokes (12) and bleeding (13 major bleeds, 41 clinically non-major bleeds) 
compared to warfarin-treated patients. Treatment costs are driven by drug acqui-
sition cost (apixaban) and monitoring cost (warfarin). ConClusions: Apixaban 
is more effective and safer than warfarin reducing the risk of stroke associated 
with AF, as well as bleeding events. To achieve this improvement, no additional 
economic resources need to be invested, which makes apixaban a cost-saving 
intervention in the context of the IMSS.
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objeCtives: Apixaban is an oral anticoagulant that has demonstrated a supe-
rior clinical profile compared to warfarin and aspirin in the management of 
patients with non-valvular Atrial Fibrilation (NVAF) and at least one additional 
risk factor for stroke. The objective of the present analysis was to assess the 
cost-effectiveness of apixaban against warfarin and aspirin for the preven-
tion of stroke in patients with NVAF in Greece. Methods: A Markov model 
that evaluated clinical events, quality adjusted life expectancy and costs for 
patients treated with apixaban and warfarin or aspirin (VKA-suitable and 
Henriksson reported that surgery plus medical management can be considered 
cost effective as a treatment of asymptomatic carotid stenosis in 65 year-old men. 
He assumed a surgery relative risk reduction of 65.5%, or approximately an abso-
lute risk reduction (ARR) of 8% in this population. However, data for the compara-
tor arm (medical management alone) were dated and did not reflect efficacies 
of current medical therapies. objeCtives: To analyze using Bayesian methods, 
asymptomatic carotid stenosis clinical trial data, and more current medical therapy 
data the probability of achieving this 8% ARR and an incremental cost per QALY 
of approximately $50,000 (US, inflated - 2013 dollars). Methods: The outcome of 
interest from the clinical trials was the mean difference in the probability of any 
stroke or perioperative death between surgery (carotid endarterectomy [CEA]) and 
aggressive medical management (MM). The CEA data came from the Asymptomatic 
Carotid Atherosclerosis Study (ACAS) and the Asymptomatic Carotid Surgery Trial 
(ACST). The updated medical management data came from a systematic review 
published in the journal Stroke (Abbott, 2009). The Bayesian analysis employed a 
Beta-Binomial Model. Results: The posterior distribution of the Bayesian analysis 
representing the ARR of CEA versus MM had a mean of 0.008 with an essentially 
zero probability of achieving the Henriksson assumption of 8% ARR. Using the mean 
of this posterior distribution, the resulting incremental cost per QALY exceeded 
$500,000 in 65 year-old men – a value unlikely to be considered cost effective in any 
country. ConClusions: Bayesian analysis allows the prediction of the probability 
that a treatment alternative exceeds a predefined threshold. A powerful feature of 
Bayesian analysis is the ability to incorporate additional and/or newer data. This 
newer data can drastically alter assumptions about the cost effectiveness of treat-
ment alternatives.
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objeCtives: Aortic stenosis is the most common valvular heart disease in the 
elderly –its prevalence is estimated to be up to 5% in individuals over 75 years. 
Surgical replacement of aortic valve is considered the standard care and in the 
absence of serious coexisting conditions, the procedure is associated with low 
operative mortality. However, a significant proportion of patients cannot undergo 
surgery due to high surgical risk associated with advanced age or presence of 
multiple coexisting conditions. Treatment with transcatheter aortic-valve implan-
tation (TAVI) is a therapy with potentially lower peri-procedure risk and has been 
used as a therapeutic option in this group considered inoperable. This study aims 
to develop a cost-effectiveness analysis of TAVI in patients with severe aortic 
stenosis who are not suitable for surgical treatment according to Brazilian Private 
System Perspective. Methods: A Markov model was developed to compare TAVI 
versus standard therapy (drug treatment with or without aortic balloon valvulo-
plasty) with a 5-year time horizon. Outcomes in the model were based on safety 
and effectiveness (as measured by clinical outcomes of chance of successful 
implantation procedure and survival from PARTNER cohort B trial). Resource use 
included early perioperative complications (30 days) and late events. Cost data 
were obtained from Brazilian public lists (CMED/SIMPRO/CBHPM). Results were 
expressed as incremental cost-effectiveness ratio (ICER) per life years gained 
(LYG). Probabilistic sensitivity analysis was performed to confirm robustness of 
results. Results: Compared with standard therapy with or without aortic balloon 
valvuloplasty, use of TAVI improves survival in 0.97 life years with an incremental 
cost of US$43,602, resulting an ICER of US$45,080/LYG. In an alternative scenario 
considering 10-year time horizon, ICER was 27,565/LYG. ConClusions: Use of 
TAVI results in improved survival with a low risk of serious adverse events, and 
demonstrates a cost-effectiveness profile when compared to other technologies 
already incorporated in Brazil.
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objeCtives: In the SHIFT trial, ivabradine administered to chronic heart failure 
(CHF) patients in combination with standard therapy significantly reduced cardio-
vascular death and hospital admission for cardiovascular problems. An economic 
evaluation of ivabradine plus standard care against standard care alone, for the 
management CHF in patients with a baseline heart rate ≥ 75b.p.m. was conducted 
from the Greek third party-payer perspective. Methods: An existing Markov model 
consisting of two health states for CHF NYHA classes I to IV (i.e. alive, dead) was 
adapted to the Greek health care setting. In each one month cycle, patients can 
either remain alive or die, during their life span or 29 months (i.e. within SHIFT 
trial period). Health state utilities were estimated from EQ-5D index scores obtained 
from the SHIFT clinical trial and using appropriate modeling techniques the data 
were extrapolated beyond the trial period. All costing data reflects the year 2013. 
Probabilistic sensitivity analyses (PSA) were conducted. Both cost and outcomes 
were discounted at 3.5% per year. Results: Results for within trial analysis 
revealed that ivabradine had an incremental cost and incremental QALY of € 905 
and 0.05 respectively, leading to an incremental cost per QALY gained of € 16,635/
QALY. Ivabradine was a cost-effective alternative at a willingness to pay thresh-
old of € 36,000 per QALY gained Moreover, the cumulated lifetime analysis showed 
incremental cost of € 2,792 and incremental QALY of 0.28. The ICER for ivabradine 
was calculated to be € 9,986 per QALY gained. The PSA showed that the likelihood 
